These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20451413)

  • 1. Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.
    Jeske S; Tagawa ST; Olowokure O; Selzer J; Giannakakou P; Nanus DM
    Urol Oncol; 2011; 29(6):676-81. PubMed ID: 20451413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study.
    Kentepozidis N; Soultati A; Giassas S; Vardakis N; Kalykaki A; Kotsakis A; Papadimitraki E; Pantazopoulos N; Bozionellou V; Georgoulias V
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):161-8. PubMed ID: 22660737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer.
    Rusarova N; Vitaskova D; Kalabova H; Ondruskova A; Purova D; Melichar B; Studentova H
    Future Oncol; 2022 Dec; 18(38):4183-4192. PubMed ID: 36519589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer.
    Sella A; Yarom N; Zisman A; Kovel S
    Oncology; 2009; 76(6):442-6. PubMed ID: 19420966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer.
    Reuter CW; Morgan MA; Ivanyi P; Fenner M; Ganser A; Grünwald V
    World J Urol; 2010 Jun; 28(3):391-8. PubMed ID: 20229232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
    Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
    Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Salvage therapy for castration-refractory prostate cancer resistant to docetaxel].
    Takayama T; Sugiyama T; Furuse H; Yajima T; Suzuki T; Kai F; Nagata M; Otsuka A; Ishii Y; Ozono S
    Nihon Hinyokika Gakkai Zasshi; 2013 Nov; 104(6):681-7. PubMed ID: 24564074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.
    Loriot Y; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Bossi A; Fizazi K
    Ann Oncol; 2009 Apr; 20(4):703-8. PubMed ID: 19179557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.
    Pectasides D; Visvikis A; Kouloubinis A; Glotsos J; Bountouroglou N; Karvounis N; Ziras N; Athanassiou A
    Eur J Cancer; 2002 Jun; 38(9):1194-200. PubMed ID: 12044505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.
    Lee JL; Ahn JH; Choi MK; Kim Y; Hong SW; Lee KH; Jeong IG; Song C; Hong BS; Hong JH; Ahn H
    Br J Cancer; 2014 May; 110(10):2472-8. PubMed ID: 24736579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer.
    Fujiwara M; Akamatsu S; Sumiyoshi T; Segawa T; Mizuno K; Yoshino T; Goto T; Sawada A; Saito R; Kobayashi T; Yamasaki T; Inoue T; Ogawa O
    Clin Genitourin Cancer; 2019 Oct; 17(5):e923-e929. PubMed ID: 31307917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial.
    Mavroudis D; Alexopoulos A; Malamos N; Ardavanis A; Kandylis C; Stavrinidis E; Kouroussis Ch; Agelaki S; Androulakis N; Bozionelou V; Georgoulias V
    Oncology; 2003; 64(3):207-12. PubMed ID: 12697959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
    Solit DB; Morris M; Slovin S; Curley T; Schwartz L; Larson S; Kattan MW; Hartley-Asp B; Scher HI; Kelly WK
    Cancer; 2003 Nov; 98(9):1842-8. PubMed ID: 14584065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
    Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M;
    Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
    Nakabayashi M; Sartor O; Jacobus S; Regan MM; McKearn D; Ross RW; Kantoff PW; Taplin ME; Oh WK
    BJU Int; 2008 Feb; 101(3):308-12. PubMed ID: 18184327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
    Sorbe B; Graflund M; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
    Int J Gynecol Cancer; 2012 Jan; 22(1):47-53. PubMed ID: 22193643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
    Ning YM; Gulley JL; Arlen PM; Woo S; Steinberg SM; Wright JJ; Parnes HL; Trepel JB; Lee MJ; Kim YS; Sun H; Madan RA; Latham L; Jones E; Chen CC; Figg WD; Dahut WL
    J Clin Oncol; 2010 Apr; 28(12):2070-6. PubMed ID: 20308663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer.
    Kawahara M; Atagi S; Komuta K; Yoshioka H; Kawasaki M; Fujita Y; Yonei T; Ogushi F; Kubota K; Nogami N; Tsuchiya M; Shibata K; Tomizawa Y; Minato K; Fukuoka K; Asami K; Yamanaka T;
    Anticancer Res; 2013 Oct; 33(10):4631-7. PubMed ID: 24123041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.